Edward B. Mulligan V Appointed to Plaintiffs’ Steering Committee for Tenofovir Drug Litigation
CohenMalad, LLP partner Edward (Ned) B. Mulligan V has been appointed to the Plaintiffs’ Steering Committee for the Judicial Council Coordination Proceeding for Gilead Tenofovir lawsuits. The coordinated proceedings are being presided over by the Honorable Andrew Y.S. Cheng in the California Superior Court for San Francisco County.
As a member of the Plaintiffs’ Steering Committee, Ned serves on a team of highly qualified lawyers from around the country that is managing the pre-trial litigation against Gilead. Ned has also been named Co-Chair of the Discovery committee and in that role will oversee the discovery process, including depositions of Gilead witnesses and the production of internal Gilead documents.
Tenofovir drugs manufactured by Gilead Sciences are sold by the brand names Truvada, Atripla, Stribild, Viread, and Complera. These drugs are prescribed to treat HIV, for pre-exposure prophylaxis (PrEP) to mitigate HIV risk, or to treat Hepatitis.
Patients who have taken these drugs have reported serious injuries including chronic kidney disease and renal failure as well as bone loss, softening of the bones, and severe fractures.
In these cases, plaintiffs allege that Gilead Sciences intentionally withheld virtually identical but far safer versions of these drugs for more than a decade so that it could profit off of the more dangerous drug before releasing the safer version.
CohenMalad, LLP attorneys have built a reputation as tough opponents in the courtroom and have a depth of experience in litigating claims for people who have been injured by dangerous drugs and medical devices. Contact us for a free case evaluation if you were prescribed tenofovir drugs manufactured by Gilead Sciences including Truvada, Atripla, Stribild, Viread, or Complera and suffered a serious injury.
